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ResearchTraumatic brain injury and the effects of diazepam, 
diltiazem, and MK-801 on GABA-A receptor subunit 
expression in rat hippocampus
Cynthia J Gibson*1, Rebecca C Meyer2 and Robert J Hamm3
Abstract
Background: Excitatory amino acid release and subsequent biochemical cascades following traumatic brain injury 
(TBI) have been well documented, especially glutamate-related excitotoxicity. The effects of TBI on the essential 
functions of inhibitory GABA-A receptors, however, are poorly understood.
Methods: We used Western blot procedures to test whether in vivo TBI in rat altered the protein expression of 
hippocampal GABA-A receptor subunits α1, α2, α3, α5, β3, and γ2 at 3 h, 6 h, 24 h, and 7 days post-injuy. We then used 
pre-injury injections of MK-801 to block calcium influx through the NMDA receptor, diltiazem to block L-type voltage-
gated calcium influx, or diazepam to enhance chloride conductance, and re-examined the protein expressions of α1, 
α2, α3, and γ2, all of which were altered by TBI in the first study and all of which are important constituents in 
benzodiazepine-sensitive GABA-A receptors.
Results: Western blot analysis revealed no injury-induced alterations in protein expression for GABA-A receptor α2 or 
α5 subunits at any time point post-injury. Significant time-dependent changes in α1, α3, β3, and γ2 protein expression. 
The pattern of alterations to GABA-A subunits was nearly identical after diltiazem and diazepam treatment, and MK-801 
normalized expression of all subunits 24 hours post-TBI.
Conclusions: These studies are the first to demonstrate that GABA-A receptor subunit expression is altered by TBI in 
vivo, and these alterations may be driven by calcium-mediated cascades in hippocampal neurons. Changes in GABA-A 
receptors in the hippocampus after TBI may have far-reaching consequences considering their essential importance in 
maintaining inhibitory balance and their extensive impact on neuronal function.
Background
Traumatic brain injury (TBI) disrupts neuronal ionic bal-
ance and is known to produce glutamate-mediated neu-
rotoxicity [1-3]. Glutamate related activation of N-
methyl-D-aspartate (NMDA) receptors and the resulting
elevations in intracellular calcium concentration ([Ca2+]i)
are important components in synaptic and cellular
degeneration and dysfunction after both in vivo [1,4,5]
and in vitro neuronal injury [6-8]. Disruption of calcium
(Ca2+) homeostasis after TBI has been implicated in a
wide range of intracellular changes in gene expression,
signaling pathways, enzymatic activation and even cellu-
lar death [see [9] for review]. Voltage gated calcium chan-
nels (VGCCs) also contribute to the increases in [Ca2+]i
identified in glutamate related neurotoxicity due to TBI
[10].
Although glutamate-related neurotoxic mechanisms
after TBI have been studied extensively, relatively little is
understood about inhibitory changes and the role of
GABA receptors. Normal neuronal function relies on the
constant orchestration and integration of excitatory and
inhibitory potentials. GABA-A receptors (GABAAR)
mediate the majority of inhibitory neurotransmission in
the central nervous system by ligand gating of fast-acting
chloride (Cl-) channels [11]. The impact of TBI on
GABAAR is poorly understood even though changes in
the composition and function of these receptors may
have extensive consequences after injury.
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The few available studies of GABAAR after TBI have
resulted in an incomplete understanding of their contri-
bution to injury-induced pathology, but have indicated
that the receptor is affected by injury. Sihver et al. [12]
found a decrease in GABAAR binding potential in the
traumatized cortex and underlying hippocampus acutely
(2 h) following lateral fluid percussion injury (FPI). Sup-
pression of long term potentiation in the hippocampus
has been demonstrated as early as 4 hours post-injury
[13], although long term depression in the CA1 was not
affected, and an overall hypoexcitation has been noted in
early measures after TBI [14]. Contrary to the reduced
inhibition in CA1 pyramidal cells [15] and CA3 to CA1
pathway [16] of the hippocampus, dentate gyrus granule
cells [15] and the entorhinal cortex to dentate gyrus path-
way demonstrated enhanced inhibition 2-15 days after
fluid percussion TBI in rats [16]. Reeves et al. also noted
that GABA immunoreactivity increased in the dentate
gyrus and decreased in the CA1 two days after injury,
correlating qualitatively with regional inhibitory changes.
It is currently unknown whether changes in constituent
GABAAR subtypes coincide with these functional
changes in hippocampal inhibition.
GABAAR can be altered by changes in [Ca2+]i, indicat-
ing that the receptors are likely to be affected by gluta-
mate-related excitotoxic effects of TBI. Specifically,
Stelzer and Shi [17] found that NMDA and glutamate
altered GABAAR currents in acutely isolated hippocam-
pal cells, and this effect was dependent on the presence of
Ca2+. Additionally, Matthews et al. [18] found the NMDA
receptor antagonist MK-801 decreased GABAAR -medi-
ated Cl- uptake in the hippocampus. Lee et al. [10] found
that the N-type VGCC blocker SNX-185 reduced the
number of degenerating neurons when injected in the
hippocampus following injury. Also, diltiazem, an FDA
approved L-type VGCC antagonist, was discovered to be
neuroprotective for cell culture retinal neurons when
administered prior to injury [19]. Diltiazem and MK-801
were found to have synergistic effects, protecting against
hypoxia-induced neural damage in rat hippocampal slices
[20].
Also connecting [Ca2+]i and GABAAR function, Kao et
al. [21] found that stretch injury of cultured cortical neu-
rons resulted in increased Cl- currents. These changes
were blocked when an NMDA antagonist or a calcium/
calmodulin protein kinase II (CaMKII) inhibitor were
present in culture. CaMKII is known to be activated by
increases in [Ca2+]i and is also known to phosphorylate
GABAAR [22]. Kao et al. [21] suggested that injury-
induced increases in glutamate activated NMDA recep-
tors, increasing [Ca2+]i and subsequently activating CaM-
KII, resulting in altered GABAAR function due to
phosphorylation of receptor proteins.
Although there is in vitro and indirect evidence that the
GABAAR is altered by TBI, there are no in vivo studies
identifying specific changes in GABAAR proteins.
GABAAR typically form a pentameric structure consist-
ing of five protein subunits surrounding a central Cl- con-
ducting ion pore. Although at least 16 subunits have been
identified, along with several splice variants of the sub-
units, the most abundant subunits in the brain typically
form a limited number of receptor combinations [23].
Reportedly, the following subunits combine to form
nearly 80% of the GABAAR combinations in the rat brain:
α1-3, β2-3, and γ2 [23-25], with α1β2γ2 and α2β2/3γ2
being the most abundant subunit combinations.
The current study utilized the in vivo FPI model to
demonstrate that GABAAR subunit proteins are altered in
the rat hippocampus after TBI. Expression of α1, α2, α3,
α5, β3, and γ2 were measured by Western blot analysis 3
hours, 6 hours, 24 hours, and 7 days post-injury. These
subunits are components in most of the GABAAR found
in the hippocampus, and were chosen based on their rela-
tive abundance and their potentially important contribu-
tions in GABAAR function. When the expression of these
proteins changed differentially due to TBI, the time point
of greatest change for the greatest number of subunits (24
h) was chosen for pharmacological manipulation. The
NMDA receptor antagonist MK-801, the L-type VGCC
antagonist diltiazem, or the GABAAR agonist diazepam
(DZ), was given prior to FPI to block Ca2+ influx or
enhance Cl- conductance. While MK-801 normalized all
subunits measured 24 hours post-TBI, diltiazem and DZ
were nearly identical in their impacts on the expression of
GABAAR subunits.
Methods
Experimental Procedures
Subjects
Adult male Sprague-Dawley rats weighing approximately
320-340 g were used for all experiments (Harlan Labora-
tories; Indianapolis, IN). Animals were housed individu-
ally in a vivarium in shoebox-type cages on a 12:12 hour
light/dark cycle. Animals in Study 1 were randomly
assigned to either the sham or injured condition and to
one of the following survival time points: 3 h, 6 h, 24 h, or
7 days (n = 3-4 per group, N = 32). Bilateral hippocampal
tissue from each animal was used to analyze expression of
all subunits. In Study 2, animals were randomly assigned
to either sham or injured with a 24 hour survival time for
each of the following treatments: no drug, MK-801
(Sigma-Aldrich), diltiazem (Henry Schein Veterinary), or
DZ (Henry Schein) (n = 3-5 per group; N = 33). Animal
care and experimental procedures were in accordance
with the National Institute of Health Guide for the Care
and Use of Laboratory Animals and the protocol was
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approved by the Institutional Animal Care and Use Com-
mittee at Creighton University, where the primary and
secondary authors were both affiliated at the time of data
collection.
Surgical Preparation and Injury
Animals were surgically prepared under sodium pento-
barbital (48 mg/kg) 24 hours prior to injury, supple-
mented as needed with 1-3% isoflurane in a carrier gas of
70% N2O and 30% O2 to maintain the surgical plane. Ani-
mals were placed in a stereotaxic frame and a sagittal
incision was made on the scalp. A craniotomy hole was
drilled over the central suture, midway between bregma
and lambda. Burr holes held two copper screws (56 × 6
mm) 1 mm rostral to bregma and 1 mm caudal to
lambda. A modified Leur-Loc syringe hub (2.6 mm inte-
rior diameter) was placed over the exposed dura and
sealed with cyanoacrylate adhesive. Dental acrylic was
applied over the entire device to secure the hub to the
skull (leaving the hub accessible). The incision was
sutured and betadine and 1% lidocaine jelly (Henry
Schein Animal Health) were applied to the wound. Ani-
mals were kept warm and continuously monitored until
they fully recovered from the anesthesia.
A central (diffuse) injury was delivered twenty-four
hours following the surgical preparation by a FPI device
described in detail by Dixon et al., [26]. The FPI model in
animals has been documented as the most common
model of TBI [27], and the central injury was chosen as a
diffuse option so bilateral hippocampi were equivalently
injured. FPI in rats produces unconsciousness, cell dam-
age to the vulnerable cortices and hippocampi, ionic cel-
lular imbalance, excitotoxic cascades, blood flow
changes, motor and memory deficits, and graded sever-
ity-dependent deficits consistent with human TBI
[28,29]. Animals were anesthetized under 3.5% isoflurane
in a carrier gas consisting of 70% N2O and 30% O2. The
surgical incision was re-opened and the animals were
connected to the fluid percussion device. Animals in the
injury groups received a moderate fluid pulse (2.1 +/- 1
atm). Sham animals were attached to the injury device
but no fluid pulse was delivered. The incision was sutured
and betadine applied. Neurological assessments includ-
ing tail, cornea, and righting reflexes were evaluated. The
animals were closely monitored until they had sufficiently
recovered and were then transferred back to the vivarium
where food and water were available ad libitum.
Western Blot Procedure
Animals were anesthetized under 3.5% isoflurane in a
carrier gas of 70% N2O and 30% O2 at the time point indi-
cated by the study design. The rats were quickly decapi-
tated and bilateral hippocampi were dissected away on
ice. The hippocampi were weighed and homogenized
with a motorized homogenizer in a buffer consisting of 3
ml RIPA lysis buffer (US Biological; Swampscott, MA)
and 30 μl Complete cocktail protease inhibitor (Roche
Molecular Biochemicals; Mannheim, Germany) per gram
of tissue.
The Western blot procedure was adapted from Kirkeg-
aard & Perry Laboratories, Inc. (KPL; Gaithersburg, MD).
Following homogenization, the hippocampi were centri-
fuged at 10,000 × g for 10 minutes. The supernatant was
removed and spun a second time at 10,000 × g for 10
minutes. Aliquots of 10 μl of lysate (the supernatant)
were stored at -20°C until used.
Following a BSA micro assay (Pierce, Rockford, IL) and
spectrophotometry to assess protein levels, all treatment
groups were run concurrently. Electrophoresis materials
(e.g., gels, buffers, membranes) were Invitrogen's NuPage
products (Carlsbad, CA), unless otherwise specified. All
primary antibodies were polyclonal, purchased from
Abcam Inc. (Cambridge, MA), and chemiluminescent
reagents were purchased from KPL. Proteins were sepa-
rated on pre-cast 4-12% Bis-Tris mini-gels using MOPS
running buffer in the Novex Mini-Cell electrophoresis
system. Separated proteins were then transferred to a
nitrocellulose membrane (90 min at 30 V). Standard
weights were run alongside each condition, including
negative controls. Negative controls consisting of a lane
that received all treatments, minus primary antibody,
were included on all blots. Following transfer, the gel was
stained with Coomassie FluorOrange (Invitrogen) to ver-
ify complete transfer to the membrane. Western blots
were run using the KPL LumiGLO Reserve Chemilumi-
nescence Kit. Primary antibody concentrations were
empirically determined as follows: α1 = 1:500, α2 = 1:200,
α3 = 1:150, β3 = 1:175, γ2 = 1:300. Several exposure
times, ranging from 5 sec to 5 min were tested to deter-
mine the clearest visualization. Digital images were
scanned and saved from the developed films. Following
immunoblotting, membranes were stained with SYPRO
Ruby stain (Sigma Aldrich, St. Louis MO) to ensure even
loading of proteins across lanes.
No protein bands were visible on any blots run under
minus primary conditions. Gel staining following protein
transfer indicated that proteins were transferred equiva-
lently across lanes. Blots revealing uneven distribution of
protein were excluded from the studies.
Drug Administration
All drugs were administered 15 minutes prior to TBI.
NMDA-mediated Ca2+ influx was blocked by administra-
tion of 0.3 mg/kg MK-801 (Tocris; Ellisville, MO) in
saline solution. This dose was previously shown to be
protective against motor deficits [2] and cognitive deficits
following fluid percussion TBI alone [30] or in combina-
tion with secondary bilateral entorhinal cortex lesions
[31]. Ca2+ influx through L-type VGCCs was blocked
Gibson et al. Journal of Biomedical Science 2010, 17:38
http://www.jbiomedsci.com/content/17/1/38
Page 4 of 11
with 5 mg/kg diltiazem, an FDA-approved drug specific
to L-type channels. Chloride conduction through the
GABAAR was enhanced using 5 mg/kg DZ, a pretreat-
ment dose previously shown to be neuroprotective
against cognitive deficits after TBI [32].
Statistical Analysis
Protein bands of approximately 60 kDa (α1), 53 kDa (α2),
53 kDa (α3), 51 kDa (α5), 50 kDa (β3), and 45 kDa (γ2)
were identified and quantified for optical density using
IMT i-Solution, Inc. software (Image and Microscope
Technology). Due to gel size constraints not all subjects
in a group could be run on the same blot, so data were
normalized as follows. At least 2 or more sham, untreated
lanes were included on all blots. Relative optical density
(ROD) of each individual protein band was quantified as
a percent difference from the value of the mean sham
density for each blot, where the mean sham density was
normalized at 100. Therefore, OD measurements for each
band in both studies were defined in ROD units, relative
to the mean sham OD per blot.
Study 1 results from α1, α3, β3, and γ2 subunits were
analyzed separately using a 2 (TBI or sham) × 4 (time)
factorial ANOVA. For α2 and α5 subunits, the 6 hour
time point was excluded based on lack of changes in all
other time points, so separate 2 (TBI or sham) × 3 (time)
factorial ANOVAs were used for analysis. In order to
determine which time point produced the greatest
change, a Fisher's LSD post-hoc was used for time point
comparisons for each subunit. The results of this analysis
indicated that the 24 hour post-injury time point revealed
the greatest changes across the most subunits. Therefore,
in Study 2 the effects of pre-injury treatment with MK-
801, diltiazem, or DZ on protein expression 24 hours fol-
lowing injury were determined using a one-factor
ANOVA and Fisher's LSD post-hoc to compare group
differences (sham-untreated, sham-treated, injured-
untreated, and injured treated) for each of the 3 drug
treatments. Due to the relative importance of γ2 and the
various α subunits to BZ-type GABAAR pharmacological
function, α1, α2, α3, and γ2 were chosen for inclusion in
Study 2. All drug treatment groups were run concurrently
with untreated sham and injured groups during Western
blot procedures to control for variation in group effects.
Results
Neurological Recovery from TBI
Analyses by ANOVA revealed that recovery of reflexes
(corneal blink, tail pinch, righting reflex), measured in
minutes, was significantly suppressed in the injured
groups compared to the sham groups. All experimental
groups demonstrated equivalent injuries as measured by
atm and reflex suppression (data not shown).
Study 1: Expression of GABAAR Subunits After TBI
No significant differences were found between sham and
injured animals for α2 or α5 relative protein densities at
any time point (Figure 1). Expression of α1 ROD in
injured hippocampus was significantly higher at 3 hours
(M = 129.72) and 6 hours (M = 114.34 and significantly
lower at 24 hours (M = 44.23) and 7 days (M = 39.81)
compared to sham (M = 100) [F(3,18) = 18.329, p < .001].
Expression of α3 subunit ROD in injured hippocampus
was significantly reduced at 24 hours (M = 74.47) com-
pared to sham [F(3,20) = 3.62, p < .05)]. No other time
points for α3 were significantly different between injured
and sham.
Expression of β3 subunit ROD in injured hippocampus
was significantly lower at 3 hours (M = 74.97) and signifi-
cantly higher at 6 hours (M = 114.87) and 24 hours (M =
118.46) compared to sham [F(3,16) = 5.319, p = .01].
There was no difference between injured and sham mea-
sures at 7 days post-injury.
Expression of γ2 subunit ROD for injured hippocampus
was significantly higher at 3 hours (M = 155.03) and sig-
nificantly lower at 24 hours (M = 69.09) compared to
sham [F(3,21) = 15.827, p < .001). There were no differ-
ences in γ2 expression between injured and sham at 6
hours or 7 days post-injury.
Study 2: Relative Optical Density of GABAAR Subunits after 
pre-TBI Drug Treatment
MK-801 pre-injury administration prevented the signifi-
cant reduction in α1, α3, and γ2 ROD 24 hours post-
injury. MK-801 had no significant effect on measures of
sham protein expression for α1 or γ2, although it signifi-
cantly decreased sham α3 expression [F(3,9) = 7.484, p <
.01]. MK-801 had no significant effect on α2 expression.
Table 1 summarizes significant group changes in protein
expression, while Figure 2 presents representative blots
and significant changes for each subunit.
Diltiazem not only prevented the significant decrease
in α1 ROD at 24 hours post-injury, but significantly
increased α1 expression in both injured (M = 162.67) and
sham (M = 133.90) compared to untreated sham [F(3,8) =
11.364, p < .01], indicating diltiazem significantly
increased α1 expression, regardless of injury condition.
Diltiazem significantly decreased α3 ROD in both injured
(M = 30.48) and sham (M = 27.38), beyond the significant
decrease seen in untreated injured hippocampus (M =
74.93) [F(3,9) = 34.13, p < .001], indicating diltiazem sig-
nificantly decreased α3 expression, regardless of injury
condition. Diltiazem normalized the significant decrease
in γ2 expression due to injury, but had no effect on γ2 in
sham hippocampus. Diltiazem had no significant effect
on α2 expression.
The effects of DZ on α1, α3, and γ2 expression were the
same as the effects of diltiazem on these subunits. DZ sig-
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Figure 1 Expression of GABAAR Subunits After TBI. Western blot analysis of GABA-A receptor subunits α1, α2, α3, α5, β3, and γ2 in the hippocam-
pus 3 h, 6 h, 24 h, or 7 days after TBI. Histograms of protein expression were measured in Relative Optical Density (ROD) proportions normalized against 
the mean sham OD for each individual blot. Asterisks indicate significant differences based on factorial ANOVA; *p < .05, **p < .01. Error bars represent 
+/-SEM. A: Alpha 1 demonstrated significantly increased expression 3 h and 6 h post-TBI followed by significantly decreased expression at 24 h and 7 
days. B: There were no significant differences in Alpha 2. C: Alpha 3 demonstrated significantly decreased expression at 24 h post-TBI only. D: There 
were no significant differences in Alpha 5. E: Beta 3 demonstrated initially significant decreased expression at 3 h, followed by significantly increased 
expression at 6 h and 24 h post injury. F: Gamma 2 demonstrated significantly increased expression at 3 h and significantly decreased expression at 
24 h post-TBI.
Gibson et al. Journal of Biomedical Science 2010, 17:38
http://www.jbiomedsci.com/content/17/1/38
Page 6 of 11
nificantly increased both sham (M = 193.48) and injured
(M = 207.19) α1 ROD 24 hours post-injury [F(3,8) =
19.624, p < .001], indicating DZ significantly increased α1
expression, regardless of injury condition. DZ also signifi-
cantly reduced α3 ROD in both sham (M = 65.65) and
injured (M = 50.93) hippocampus beyond the injury-
induced decrease in expression (M = 74.93) [F(3,9) =
14.907, p < .01], indicating DZ decreased α3 expression,
regardless of injury condition. DZ normalized γ2 injury-
induced decreases in ROD without significantly effecting
Figure 2 GABAAR Subunits After pre-TBI Drug Administration. Western blot analysis of GABA-A receptor subunits α1, α2, α3, and γ2 in the hip-
pocampus 24 h post-TBI with either no drug (untreated), MK-801 (NMDA calcium blocker, 0.3 mg/kg), diltiazem (L-type VGCC antagonist, 5 mg/kg), 
or diazepam (GABA-A agonist, 5 mg/kg). Histograms of protein expression were measured in Relative Optical Density (ROD) proportions normalized 
against the mean sham OD for each individual blot. Each blot contained at least 2 sham and 1 injured untreated protein lanes. Tissue from the same 
sham and injured groups was used for comparison to each drug by ANOVA. Asterisks indicate significant differences based on factorial ANOVA; *p < 
.05, **p < .01. Error bars represent +/-SEM. A: MK-801 normalized alpha 1 expression, while diltiazem and diazepam significantly increased expression 
in both sham and injured animals. B: No alpha 2 injury effects or drug effects were found for MK-801 or diltiazem, although diazepam significantly 
increased alpha 2 expression in both sham and injured animals. C: MK-801 significantly decreased alpha 3 expression in sham but not injured animals, 
while diltiazem and diazepam significantly decreased expression in both sham and injured animals. D: Gamma 2 expression was normalized by all 
drug treatments.
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sham γ2 expression. DZ had the unique effect of signifi-
cantly increasing α2 expression in both sham (M =
249.62) and injured (M = 252.89) hippocampal tissue,
indicating DZ significantly increased α2 expression, even
though there was no injury effect on this subunit.
Discussion
The hypothesis that TBI would differentially alter
GABAAR subunit expression in the hippocampus in a
time-dependent manner was supported. Both α1 and γ2
subunit expression increased acutely after injury, but
were significantly decreased by 24 h, while α3 and β3
showed time-specific transient changes and α2 and α5
subunits were not altered significantly at any time point.
MK-801 prevented changes to all subunits studied 24
hours after TBI, while diltiazem and DZ treatments had
nearly identical effects, normalizing γ2 and altering α1
and α3 expression. DZ also significantly increased α2
expression in both sham and injured animals.
Study 1: Expression of GABAAR Subunits After TBI
This study is the first to demonstrate time-dependent in
vivo GABAAR protein expression changes due to TBI.
Most predominant GABA-A subunits have been identi-
fied as having specific physiological relevance, often
through the use of knockout and knockdown animals.
Differential changes in subunits may have important rele-
vance since GABAAR subunits regulate different func-
tions. The β subunit of the GABAAR is vital for the
regulation of ion selectivity and general properties of the
chloride channel [33,34], as evidenced by β3 knockout
mice developing epilepsy, a disorder associated with a
disruption in the ionic balance in the cells [25]. The β
subunits also differentially regulate inhibitory Cl- flow
[35]. The transitory increase in β3 expression at 3 hours
and decrease at 6 and 24 hours post-injury may be related
to time-dependent alterations in inhibitory functioning,
although further measures of other β subunits and their
influence on inhibitory function are still needed.
The γ subunit differentially regulates benzodiazepine
(BZ) sensitivity with γ2 knockdown mice showing
reduced BZ binding [36] and γ1 and γ3 not demonstrat-
ing any BZ activity [37]. The γ2 subunit is also endoge-
nously required for the clustering of receptors at the
synapse [38]. Therefore, the initial increase in γ2 expres-
sion 3 hours post-TBI, followed by a decrease at 24 hours
may indicate greater γ2-containing GABAAR clustering
and greater BZ binding potential during the first few
hours after injury, therefore providing a widow of initial
therapeutic sensitivity for BZ treatment post-TBI.
The α subunit of the GABAAR is important for post-
synaptic signaling of the receptors [39] and specific
effects of BZs such as DZ [40]. Additionally, the various α
subunits have a wide range of unique functions. Con-
strained mainly to hippocampal neurons, α5 regulates
hippocampal dendritic pyramidal inhibition related to
learning and memory plasticity [41]. Since hippocam-
pally-driven deficits in learning and memory are well
demonstrated after TBI, it is important to note that α5
subunit expression did not change at any time point stud-
ied. This may indicate relative stability of this subunit, or
the changes may be regionally specific and therefore not
detected in the whole hippocampal homogenate used in
this study. The α3 subunit contributes to GABAergic
inhibition of dopamine neurons, and genetic ablation of
α3 subunits is found to cause disruptions in sensory gat-
ing as measured through pre-pulse inhibition of acoustic
startle [41]. Since decreases in α3 were found only at the
24 hour time point, this may indicate a time-dependent
fluctuation in GABA-dopamine interaction during the
shift from acute to chronic post-injury measurements.
Found mainly in the amygdala, α2 exerts some control
over emotional functioning [42], which may help explain
its anxiolytic role in BZ action [25]. Additionally, the α2
subunit is highly expressed in the ventral hippocampus
which has been found to exert weaker inhibitory tone and
has higher seizure susceptibility compared to the dorsal
hippocampus, which primarily expresses α1 [35]. This
study focused on mild/moderate TBI and no post-injury
seizure activity was detected, which may partially explain
why α2 expression was unaffected. However, deficits in
excitatory/inhibitory balances in neurotransmission in
the hippocampus have been found even in mild TBI, and
were believed to contribute to both increased seizure sus-
ceptibility and cognitivdeficits [43].
Table 1: Summary of significant changes in GABAAR 
subunit ROD 24 hours after TBI or Sham injury
α1 α2 α3 γ2
Sham-Untreated - - - -
Injured-Untreated  -  
Sham+MK801 - -  -
Injured+MK801 - - - -
Sham+diltiazem  -  -
Injured+diltiazem  -  -
Sham+DZ    -
Injured+DZ    -
Double arrows indicate a drug-induced significant change 
beyond effects due to TBI only (i.e, compared to the injured 
untreated group). DZ and Diltiazem treatment had identical 
patterns of significance for all subunits except α2, which had 
significantly increased expression due to DZ treatment. MK-801 
normalized all TBI-induced significant changes in protein 
expression.
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The most widespread α subunit with the most diversely
documented functional implications is α1, which is highly
expressed in the dorsal hippocampus where it likely con-
tributes to greater GABA binding and lower seizure sus-
ceptibility [35]. Also, α1 plays an important role in
development [44], so changes in α1 subunit levels may be
indicative of a partial reversion of certain GABAergic
receptors to a more developmental state. This is an
intriguing possibility since GABA activity can be excit-
atory during development [45]. Excitatory GABAergic
signaling has already been proposed as a contributor to
the pathophysiology of epilepsy [46]. Persistent altera-
tions in inhibitory balance after TBI have been implicated
in increased post-injury development of epilepsy
[43,47,48] and in cognitive memory deficits [43,49,15].
Just as different subunits have unique effects on GABA-
A function, their differential alteration following TBI can
have specific implications for the pathophysiological state
of the recovering brain. Thompson et al. [50] demon-
strated differential mRNA changes for GABAAR subunits
in cultured cerebellar granule cells exposed to protein
kinase A. Protein kinase A inhibitors prevented these
effects on α1 but not on α6, indicating differential regula-
tory mechanisms for different subunits. Epilepsy research
has also demonstrated disparate alterations in subunits.
Although β3 mRNA decreased in the hippocampus fol-
lowing kainic acid-induced seizures, α1 mRNA increased
in the interneurons of the dentate gyrus and CA3 [51].
Huopaniemi et al. [52] demonstrated more than 130 tran-
scriptional changes in α2, α3, and α5 in α1 point-mutated
mice after a single DZ injection, although there was no
effect in wild type mice. Therefore, in the absence of spe-
cific α1 genes, other α subunit transcripts changed, indi-
cating a complicated compensatory relationship among α
subunits [52].
The α1 subunit was the only one to demonstrate signif-
icant changes at every time point studied. This is impor-
tant because α1 may mediate apoptosis via the
endoplasmic reticulum (ER) stress pathway [53]. Since
the cells in the current study were lysed to obtain whole
protein measures, regional specificity of each protein
cannot be determined and therefore the changes may also
represent subunits in the ER. Overexpression of α1 may
be related to apoptotic processes after TBI. Also, α1 over-
expression can trigger apoptosis due to a complicated
relationship with c-myc, a proto-oncogene that regulates
cellular proliferation and apoptosis. The α1 gene is a
direct target for suppression by c-myc and mRNA expres-
sion is inversely related to c-myc expression. This inverse
balance between c-myc and α1 may be either a marker or
a key player in the developmental cessation of neuronal
pruning. Shifts in c-myc expression during neuronal
insult such as TBI may result in changes to the α1 gene,
independent of its role in GABAAR function. Over-
expression of α1 has also been associated with apoptosis
in a Ca2+-dependent manner. Specifically, disruption of
ER Ca2+ balance may alter α1 mRNA, producing an
increase that activates caspase 3 and induces apoptosis
[53]. Therefore, blocking Ca2+ influx due to TBI may pre-
vent α1-associated apoptosis by preventing significant
increases in α1 subunit proteins.
Alterations in α1 expression may also affect the func-
tion of the GABAAR. Increases in α1 mRNA and protein
expression during development correspond to increases
in BZ binding and altered zinc sensitivity [54], while
reduced α1 mRNA and protein expression in the hip-
pocampus of seizure-prone animals is associated with
reduced inhibitory tone [55]. Increased α1 subunits may
also contribute to pronounced sedative or amnesic effects
associated with BZs without any effect on the anxiolytic
or relaxant properties [56,57]. Since changes in α1 pro-
tein expression were different during acute (3 h, 6 h) and
chronic (24 h, 7 day) post-injury time points, there may
be important implications for the timing of BZ use in TBI
patients. O'Dell and Hamm [58] found that DZ adminis-
tered around the time of injury significantly improved
mortality and cognitive outcome in a water maze task 2
weeks after FPI. However, chronic treatment with Surito-
zole, a negative GABAAR modulator similar to BZ inverse
agonists, starting 24 hours post injury was also cogni-
tively beneficial in the water maze [58]. Increased α1 and
γ2 within 3 hours of TBI in this study may indicate a shift
in GABAAR constituent proteins to a more BZ-sensitive
composition. This could prime GABAAR for greater sen-
sitivity to BZs and increased Cl- conductance, while the
decrease in α1 and γ2 at 24 hours may be an attempt to
compensate for chronic hypofunctioning by reducing
GABAAR sensitivity. Novel compounds that target spe-
cific subtypes or subunits of GABAAR may provide more
insight into their roles after TBI.
Alteration to GABAAR expression may be due to phos-
phorylation of subunit proteins. Increases in glutamate
after injury trigger VGCC and NMDA receptors, increas-
ing [Ca2+]i, and resulting in activation of CaMKII. A sin-
gle dose of DZ can downregulate CaMKIIα transcription
quickly and persistently, although this downregulation of
CaMKIIα transcripts in wild type mice is not found in
mice with point mutations to GABAAR α1 [52]. Folkerts
et al. [59] found that fluid percussion TBI increased both
CaMKIIα and total CaMKII in the hippocampus,
although this increase was transient with CaMKII eleva-
tions no longer significant by 3 hours post-injury. Protein
phosphatases such as calcineurin also increase after TBI
due to activation by elevated [Ca2+]i [60]. Folkerts et al.
[59] proposed protein phosphatase activation, including
calcineurin, may explain the unusual pattern of CaMKII
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immunostaining in CA3 pyramidal cells in the hippocam-
pus after TBI.
Study 2: GABAAR Subunits After pre-TBI Drug 
Administration
A single pre-injury injection of MK-801 normalized
GABAAR subunit expression. Therefore, blockade of Ca2+
influx through the NMDA receptor effectively attenuated
α1, α3, and γ2 subunit decreases 24 hours post-injury,
indicating that injury-related influx of Ca2+ through the
NMDA receptor contributed to the changes in GABA-A
subunit expression. There may be diverse regulatory
mechanisms involved in the interaction between NMDA
receptors and GABAAR. Kim et al. [61] found chronic
blockade of Ca2+ influx through the NMDA receptor with
MK-801 reduced β3 and increased β2 mRNA but not
protein expression in the hippocampus. Chronic MK-801
treatment did not alter GABA-A α1 or NMDA receptor
subunit mRNA or protein expression in the hippocampus
but GABAAR-mediated Cl- uptake was still significantly
decreased [18].
Although this study was not designed to determine the
specific mechanism by which elevated [Ca2+]i resulted in
alterations to GABAAR subunits, we do know that ele-
vated [Ca2+]i alters numerous intracellular mechanisms
following TBI [9], including activation of apoptotic fac-
tors, CaMKII, and protein phosphatases. Although Ca2+
influx through the NMDA receptor is a major source of
neuronal excitotoxicity [6], other sources of Ca2+ influx
may also be important. For example, VGCC blockers
have been shown to be beneficial after TBI [10,62].
Diltiazem, an L-type VGCC blocker, and DZ, a
GABAAR agonist, had statistically identical effects on the
expression of GABAAR subunits α1, α3, and γ2, normaliz-
ing γ2 and significantly increasing α1 and decreasing α3.
Changes to α1 and α3 occurred in both sham and injured
animals, indicating drug effects that overrode the injury
effects. Some L-type channel blockers have known effects
on receptors such as NMDA [63] or GABA-A [64], but
diltiazem has been shown to have no direct effect on
recombinant α1β2γ2 receptors [65]. However, VGCC
regulation of GABAAR surface expression may be a com-
mon mechanism since it has been implicated after
hypoxia [66] and extended GABA exposure [67]. There-
fore, the similar profiles of GABAAR changes for dilti-
azem and DZ are likely due to similarities of action that
alter excitatory/inhibitory balance, rather than a direct
effect on the GABAAR.
Both diltiazem and DZ inhibit Ca2+ release induced by
sodium presence in rat brain mitochondria [68] by inhib-
iting mitochondrial Ca2+ efflux via the sodium/calcium
exchanger [68,69]. One method of buffering excessive
increases in [Ca2+]i after TBI is to sequester Ca2+ into
organelles such as the mitochondria. Calcium, however,
can damage the mitochondria, resulting in several detri-
mental consequences, including the release of pro-apop-
totic factors [9]. Through the enhancement of GABA-A
Cl- influx, DZ regulates Ca2+ and apoptotic factor release
from the mitochondria, providing neuroprotection after
in vivo ischemia and in vitro glutamate or oxidative stress
in CA1 hippocampal and brain slices, respectively [70].
This DZ regulation of mitochondrial Ca2+ release likely
plays an important role in vivo after TBI as well.
Diltiazem and MK-801 have synergistic neuroprotec-
tion against hypoxia in rat hippocampal slices, beyond
simple additive effects [20]. Diltiazem [71] and MK-801
[72] both reduced excitotoxic effects of glutamate and
NMDA exposure in a cell culture model of hypoxia.
Although diltiazem did not block NMDA receptors, it
was more effective in reducing NMDA-mediated than
glutamate-mediated Ca2+ influx, and was more effective
at lower doses than MK-801 at regulating glutamate-
mediated Ca2+ influx. The effectiveness of diltiazem high-
lights the importance of non-NMDA sources of intracel-
lular Ca2+ influx. Opening of VGCCs can trigger removal
of the NMDA receptor magnesium blockade, with
NMDA receptor-mediated influx of Ca2+ further depolar-
izing VGCCs. Diltiazem, therefore, blocks L-type VGCCs
at initial and continuing stages of Ca2+ entry. Due to rela-
tive safety and potential benefits, both diltiazem and DZ
may have therapeutic potential acutely following TBI, but
more information is needed to understand the mecha-
nism of neuroprotection, influence on cascades, and
impact on behavioral outcome. Evidence indicates the
timing of administration of these drugs will be crucial.
Conclusions
The current studies are the first to demonstrate that TBI
induces time-dependent changes in GABAAR α1, α3, β3,
and γ2, but not α2 or α5 expression during the first 7 days
after injury. The changes in GABAAR protein expression
found in these studies may have important consequences
for post-injury apoptosis in the hippocampus, as well as
neuronal excitability and pharmacological responsiveness
after TBI. These studies, therefore, support the hypothe-
ses that TBI alters the constituent proteins of the
GABAAR and that these alterations may be driven by a
calcium-mediated mechanism.
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